



## Infectious Disease Immunotherapy Research

Guest Editor:

**Dr. Ravi S. Misra**

Division of Neonatology,  
Department of Pediatrics,  
University of Rochester Medical  
Center, Rochester, NY 14642, USA

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editor

The ability to modulate the immune response has received a great deal of research focus recently. Examples include the use of adjuvants to increase immunogenicity of vaccines, nanoparticles to deliver SARS-CoV-2 mRNA vaccines, the use of recombinant cytokines to boost antiviral responses, and checkpoint inhibitors to enhance immune responses against infectious agents in immunocompromised individuals. Other factors can be used to control and overexuberant or misguided immune response. Examples include the use of cytokine-neutralizing antibodies, steroids, and inhibitors of targeted pathways (e.g., inflammasomes, toll-like receptors, cytokine receptors). Researchers are now well positioned to utilize these methods to better understand the mechanisms behind maintaining a fine balance between controlling pathogens and limiting collateral damage. This will allow for the more rapid development of immunomodulatory therapeutics that will advance human health. This Special Issue of *Vaccines* is dedicated to highlighting studies that focus on modulating the immune response against infectious agents.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)